Responsiveness of intrinsic subtypes to adjuvant anthracycline substitution in the NCIC.CTG MA.5 randomized trial. (Q37095799)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22351696%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

title

Responsiveness of intrinsic subtypes to adjuvant anthracycline substitution in the NCIC.CTG MA.5 randomized trial (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22351696%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22351696%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Maggie Chon U Cheang

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22351696%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Sherri R Davies

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22351696%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Mark Ebbert

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22351696%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

author name string

K David Voduc

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22351696%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Dongsheng Tu

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22351696%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Shan Jiang

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22351696%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Samuel Leung

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22351696%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Stephen K Chia

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22351696%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Lois E Shepherd

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22351696%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Mark N Levine

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22351696%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Kathleen I Pritchard

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22351696%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Inge J Stijleman

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22351696%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Carole Davis

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22351696%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Joel S Parker

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22351696%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Matthew J Ellis

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22351696%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Philip S Bernard

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22351696%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Torsten O Nielsen

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22351696%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

language of work or name

English

0 references

publication date

20 February 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22351696%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

published in

Clinical Cancer Research

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22351696%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

volume

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22351696%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

page(s)

2402-2412

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22351696%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22351696%20AND%20SRC:MED&resulttype=core&format=json

Breast cancer in Brazil: present status and future goals

23 January 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3743660

HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3743660

Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3743660

A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3743660

CEF is superior to CMF for tumours with TOP2A aberrations: a Subpopulation Treatment Effect Pattern Plot (STEPP) analysis on Danish Breast Cancer Cooperative Group Study 89D.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3743660

Classical cyclophosphamide, methotrexate, and fluorouracil chemotherapy is more effective in triple-negative, node-negative breast cancer: results from two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3743660

Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3743660

Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3743660

Supervised risk predictor of breast cancer based on intrinsic subtypes

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3743660

Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3743660

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3743660

Breast cancer subtypes and the risk of local and regional relapse.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3743660

The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3743660

Breast cancer molecular subtypes respond differently to preoperative chemotherapy

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3743660

Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3743660

Breast cancer molecular subclassification and estrogen receptor expression to predict efficacy of adjuvant anthracyclines-based chemotherapy: a biomarker study from two randomized trials

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3743660

HER2 and responsiveness of breast cancer to adjuvant chemotherapy.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3743660

Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3743660

Reporting recommendations for tumor marker prognostic studies (REMARK).

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3743660

Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Gr

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3743660

Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Cli

3 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22351696

12 December 2020

inferred from PubMed ID database lookup

Identifiers

DOI

10.1158/1078-0432.CCR-11-2956

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/dodlzfs36reeznnch3aa5mrmpu

30 July 2022

release_dodlzfs36reeznnch3aa5mrmpu

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/dodlzfs36reeznnch3aa5mrmpu

30 July 2022

https://api.fatcat.wiki/v0/release/dodlzfs36reeznnch3aa5mrmpu

1 reference

30 July 2022

https://api.fatcat.wiki/v0/release/dodlzfs36reeznnch3aa5mrmpu

1 reference

30 July 2022